Keolie Supply 866460-33-5 Seripiprant

Message

$60.00

Have chosenThere are no options selected.

Start To Order

Add To Cart Successfully!

SEND INQUIRY
Keolie Supply 866460-33-5 Seripiprant
Keolie Supply 866460-33-5 Seripiprant
Keolie Supply 866460-33-5 Seripiprant
Keolie Supply 866460-33-5 Seripiprant
Keolie Supply 866460-33-5 Seripiprant
Keolie Supply 866460-33-5 Seripiprant
Keolie Supply 866460-33-5 Seripiprant

Keolie Supply 866460-33-5 Seripiprant

  • Item No.KL-Seripiprant
    MOQ10 Gram
Tag  sourcing
Add Request About This Product
Max file 5MB each
If lager file please send us email

Quantity:

From $60.0045.00 / Gram
$600.00
You save $ -600.00
Trade Assuranceprotects your orders
Payments:
Order protection service which protects online orders when payment is made through Alibaba's Trade Assurance. Learn More
Trade Assurance reduces risks in:
Product Quality On-Time Shipment

If you have your own design, please contact us, there will have a professional customer service to communicate with you.

Don't have your files right now?No worries, Check out our art tips for more information.

If over 500pcs, mass production will start until pre-production sample has been approved.

Est. 7 days production

Quick Details
Product name Seripiprant
Place of Origin CN;SHA
Usage Animal Pharmaceuticals
Brand Name Keolie
Specification99%
Appearance White Powder
Assay HPLC 99%
Model Number KL-Seripiprant
SampleAvailiable
StorageCool
MOQ10gram
CertificateISO
Shelf Life 2 Years
Type Vitamins, Amino Acids and Coenzymes
Grade Standard Medicine Grade
CAS No. 866460-33-5
Grade Phamaceutical Grade
Other Names Seripiprant
MF866460-33-5
EINECS No. 866460-33-5
Purity99%

Packaging & Delivery

Selling Units:
Gram
Lead Time:
Quantity(Gram)1 - 100101 - 500>500
Est. Time(days)34To be negotiated

Keolie Supply 866460-33-5 Seripiprantintroduce.jpg

Setipiprant is a drug originally developed by Actelion which acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2). It was initially researched as a treatment for allergies and inflammatory disorders, particularly asthma, but despite being well tolerated in clinical trials and showing reasonable efficacy against allergen-induced airway responses in asthmatic patients, it failed to show sufficient advantages over existing drugs and was discontinued from further development in this application.

However, following the discovery in 2012 that the prostaglandin D2 receptor (DP/PGD2) is expressed at high levels in the scalp of men affected by male pattern baldness, the rights to setipiprant were acquired by Kythera with a view to potentially developing this drug as a novel treatment for baldness, with a previously unexploited mechanism of action. While it is too early to tell whether setipiprant will be an effective treatment for this condition, the favorable pharmacokinetics and relative lack of side effects seen in earlier clinical trials mean that fresh clinical trials for this new application can be conducted fairly quickly

Product name: Setipiprant
CAS NO: 866460-33-5
Grade: Medicine Grade 

Function:Hair loss treatment

function.jpg

Seripiprant

other name:anti-hair loss powder

CAS:866460-33-5company details.jpgcontact.jpgpackage&shipping.jpg

No need register, just fill in contact info below, we will reply you within 24 hours!

Enter the code in the box below: